This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Johnson, B. E. Articles by Cashell, A. W. Search for Related Content PubMed PubMed Citation Articles by Johnson, B. E. Articles by Cashell, A. W.

myc Family DNA Amplification in Small Cell Lung Cancer Patients' Tumors and Corresponding Cell Lines¹

NCI-Navy Medical Oncology Branch, National Cancer Institute and Naval Hospital [B. E. J., A. D. S., A. F. G.], Pathology Department, Naval Hospital [D. B., A. W. C.], Bethesda, Maryland 20814, and the Division of Biostatistics, Yale University School of Medicine [R. W. M.], New Haven, Connecticut 06510

Tumor specimens procured from 38 different small cell lung cancer patients were studied for DNA amplification of the myc family of protooncogenes (c-myc, N-myc, and L-myc). Six of the 38 specimens (16%) had 4-fold or greater myc family DNA amplification (N-myc in 4 and L-myc in 2). All 6 tumors with amplification came from patients who had received combination chemotherapy. The myc family gene copy number of the DNA prepared from 9 tumor cell lines established from these 38 patients was similar to the myc family gene copy number in the DNA prepared from fresh tumor specimens from these same patients. myc family DNA amplification is present in 16% of small cell lung cancer patients' tumors and the amplification pattern in the tumor cell lines is representative of the fresh tumors obtained from the same patients.

¹ The opinions and assertions contained herein are the private views of the authors and are not to be construed as official or reflecting the views of the Department of the Navy or the Department of Defense.

² To whom requests for reprints should be addressed, at NCI-Navy Medical Oncology Branch, Building 8, Room 5101, Naval Hospital, Bethesda, MD 20814.

³ Supported in part by Grant 5P30-CA-16359 from the National Cancer Institute.

Received 6/26/87. Revised 3/15/88. Accepted 6/16/88.

This article has been cited by other articles:

				E. T. Olejniczak, C. Van Sant, M. G. Anderson, G. Wang, S. K. Tahir, G. Sauter, R. Lesniewski, and D. Semizarov Integrative Genomic Analysis of Small-Cell Lung Carcinoma Reveals Correlates of Sensitivity to Bcl-2 Antagonists and Uncovers Novel Chromosomal Gains Mol. Cancer Res., April 1, 2007; 5(4): 331 - 339. [Abstract] [Full Text] [PDF]

				M. I. Lerman and J. D. Minna The 630-kb Lung Cancer Homozygous Deletion Region on Human Chromosome 3p21.3: Identification and Evaluation of the Resident Candidate Tumor Suppressor Genes Cancer Res., November 1, 2000; 60(21): 6116 - 6133. [Abstract] [Full Text]

				P. Schraml, J. Kononen, L. Bubendorf, H. Moch, H. Bissig, A. Nocito, M. J. Mihatsch, O.-P. Kallioniemi, and G. Sauter Tissue Microarrays for Gene Amplification Surveys in Many Different Tumor Types Clin. Cancer Res., August 1, 1999; 5(8): 1966 - 1975. [Abstract] [Full Text] [PDF]

				I. I. Wistuba, D. Bryant, C. Behrens, S. Milchgrub, A. K. Virmani, R. Ashfaq, J. D. Minna, and A. F. Gazdar Comparison of Features of Human Lung Cancer Cell Lines and Their Corresponding Tumors Clin. Cancer Res., May 1, 1999; 5(5): 991 - 1000. [Abstract] [Full Text] [PDF]